Human serum albumin-based design of a diflunisal prodrug

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 3, 2013, Pages 549-554

  Yang, Feng ^a   Ma, Zhi Yuan ^a   Zhang, Yao ^a   Li, Guo Qing ^a,b   Li, Mei ^a   Qin, Jiang Ke ^a   Lockridge, Oksana ^b   Liang, Hong ^a  

^a GUANGXI NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Acetylation; Acetyldiflunisal; Crystal structure; Lysine 199 of albumin; Prodrug design

Indexed keywords

ACETYLDIFLUNISAL; DIFLUNISAL; FATTY ACID; HUMAN SERUM ALBUMIN; LYSINE; PRODRUG; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; FLUORESCENCE; MASS SPECTROMETRY; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE INHIBITORS; DIFLUNISAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS; HUMANS; HYDROGEN-ION CONCENTRATION; LIGANDS; LYSINE; PRODRUGS; PROTEIN STRUCTURE, TERTIARY; SERUM ALBUMIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84879097273     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.01.013     Document Type: Article

References (33)

1. T. Peters All about Albumin: Biochemistry, Genetics, and Medical Applications 1995 Academic Press San Diego
2. G. Colmenarejo In silico prediction of drug-binding strengths to human serum albumin Med. Res. Rev. 3 2003 275 301
3. G. Mahesh, and S. Rajagopal Molecular interaction studies of trimethoxy flavone with human serum albumin PLoS ONE 1 2010 8834 8842
4. T. Oltersdorf, and S.-H. Rosenberg An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
5. X.-M. He, and D.-C. Carter Atomic structure and chemistry of human serum albumin Nature 358 1992 209 215
6. J. Ghuman, P.-A. Zunszain, and S. Curry Structural basis of the drug-binding specificity of human serum albumin J. Mol. Biol. 353 2005 38 52
7. S. Yamaguchi, and K. Uchida Delta12-prostaglandin J2 as a product and ligand of human serum albumin: formation of an unusual covalent adduct at His146 J. Am. Chem. Soc. 132 2010 824 832
8. S. Curry Lessons from the crystallographic analysis of small molecule binding to human serum albumin Drug Metab. Pharmacokinet. 24 2009 342 357
9. A.-J. Ryan, P.A. Zunszain, and S. Curry Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin J. Struct. Biol. 174 2011 84 91
10. P.A. Zunszain, J. Ghuman, A.F. McDonagh, and S. Curry Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-Ixalpha J. Mol. Biol. 381 2008 394 406
11. A. Varshney, P. Sen, E. Ahmad, M. Rehan, N. Subbarao, and R.-H. Khan Ligand binding strategies of human serum albumin: how can the cargo be utilized? Chirality 22 2010 77 87
12. S. Curry X-ray crystallography of albumin in human serum albumin - new insights on its structural dynamics M. Otagiri, Functional Impacts and Pharmaceutical Applications 2011 Sojo Univ kumamoto, Japan 1 29
13. G.-C. Roberts NMR spectroscopy in structure-based drug design Curr. Opin. Biotechnol. 10 1999 42 47
14. R.-E. Hubbard Can drugs be designed? Curr. Opin. Biotechnol. 8 1997 696 700
15. H. Mao, P.J. Hajduk, R. Craig, R. Bell, T. Borre, and S.W. Fesik Rational design of diflunisal analogues with reduced affinity for human serum albumin J. Am. Chem. Soc. 123 2001 10429 10435
16. J. Hannah, W.V. Ruyle, H. Jones, A.R. Matzuk, K.W. Kelly, B.E. Witzel, W.J. Holtz, R.W. Houser, T.Y. Shen, and L.H. Sarett Discovery of diflunisal Br. J. Clin. Pharmacol. Suppl. 1 1977 7S 13S
17. J. Hannah, W.V. Ruyle, H. Jones, A.R. Matzuk, K.W. Kelly, B.E. Witzel, W.J. Holtz, R.A. Houser, T.Y. Shen, and L.H. Sarett Novel analgesic- antiinflammatory salicylates J. Med. Chem. 21 1978 1093 1100
18. A.G. Gilman, T.W. Rall, A.S. Nies, and P. Taylor The Pharmacological Basis of Therapeutics eighth ed. 1990 Pergamon Press New York
19. F. Yang, C. Bian, L. Zhu, G. Zhao, Z. Huang, and M. Huang Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin J. Struct. Biol. 157 2007 348 355
20. J.E. Walker Lysine residue 199 of human serum albumin is modified by acetylsalicyclic acid FEBS Lett. 66 1976 173 175
21. M.S. Liyasova, L.M. Schopfer, and O. Lockridge Reaction of human albumin with aspirin in vitro: mass spectrometric identification of acetylated lysines 199, 402, 519, and 545 Biochem. Pharmacol. 79 2010 784 791
22. S. Curry, H. Mandelkow, P. Brick, and N. Franks Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites Nat. Struct. Biol. 5 1998 827 835
23. W.L. DeLano The PyMol Molecular Graphics System 2004 DeLano ScientiWc San Carlos, CA
24. O.K. Abou-Zied, and O.I. AlShihi Characterization of subdomain IIA binding site of human serum albumin in its native, unfolded, and refolded states using small molecular probes J. Am. Chem. Soc. 130 2008 10793 10801
25. F. Zsila, Z. Bikádi, and M. Simonyi Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods Biochem. Pharmacol. 65 2003 447 456
26. T. Chatterjee, A. Pal, S. Dey, B.K. Chatterjee, and P. Chakrabarti Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling PLoS ONE 7 2012 e38372
27. A.A. Bhattacharya, T. Grune, and S. Curry Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin J. Mol. Biol. 303 2000 721 732
28. J.R. Simard, P.A. Zunszain, J.A. Hamilton, and S. Curry Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis J. Mol. Biol. 361 2006 336 351
29. J.R. Simard, P.A. Zunszain, C.E. Ha, J.S. Yang, N.V. Bhagavan, I. Petitpas, S. Curry, and J.A. Hamilton Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy Proc. Natl. Acad. Sci. USA 102 2005 17958 17963
30. D. Fredrickson, and S. Gordon The metabolism of albumin-bound C14-labeled unesterified fatty acids in normal human subjects J. Clin. Invest. 37 1958 1504 1515
31. B. Elsadek, and F. Kratz Impact of albumin on drug delivery - new applications on the horizon J. Control. Release 157 2012 4 28
32. F. Kratz, and B. Elsadek Clinical impact of serum proteins on drug delivery J. Control. Release 161 2012 429 445
33. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183